{"id":"triptans","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 3 times"},{"date":"","signal":"ARTERIOSPASM CORONARY","source":"FDA FAERS","actionTaken":"Reported 2 times"},{"date":"","signal":"CARDIAC FAILURE","source":"FDA FAERS","actionTaken":"Reported 2 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 2 times"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"Reported 2 times"},{"date":"","signal":"ACNE CYSTIC","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"ALTERED STATE OF CONSCIOUSNESS","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"AMNESIA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"AUTONOMIC NERVOUS SYSTEM IMBALANCE","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Ergotamines","action":"Avoid","effect":"Increased risk of vasospasm and ischemia"},{"drug":"Selective serotonin reuptake inhibitors (SSRIs)","action":"Monitor","effect":"Increased risk of serotonin syndrome"},{"drug":"Monoamine oxidase inhibitors (MAOIs)","action":"Avoid","effect":"Increased risk of serotonin syndrome"},{"drug":"CYP1A2 inhibitors (e.g., fluvoxamine)","action":"Monitor","effect":"Increased triptan levels and risk of adverse effects"},{"drug":"CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Monitor","effect":"Increased triptan levels and risk of adverse effects"},{"drug":"CYP2D6 inhibitors (e.g., paroxetine)","action":"Monitor","effect":"Increased triptan levels and risk of adverse effects"},{"drug":"Other triptans","action":"Avoid","effect":"Increased risk of serotonin syndrome and vasospasm"}],"commonSideEffects":[],"contraindications":["ischemic heart disease","vasospastic coronary disease","previous myocardial infarction","stroke","transient ischemic attack (TIA)","peripheral vascular disease","uncontrolled hypertension","ergot-containing medications","MAO-A inhibitors","other 5-HT1 agonists","pregnancy","hemiplegic or basilar migraine"],"specialPopulations":{"Pregnancy":"Triptans in Pregnancy: New Study Finds No Long-Term Developmental Risks. Researchers in Norway examined over 26,000 pregnancies among women with migraine, tracking their children’s health from birth up to 14 years of age. The study found no clear evidence that prenatal triptan exposure harms children’s development into childhood and adolescence.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=triptans","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:13.740509+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Triptans","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:40:23.053697+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:40:31.271351+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:21.542766+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:13.762258+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=triptans","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:22.286354+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297446/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:22.760799+00:00"}},"offLabel":[],"timeline":[{"date":"1940s","type":"neutral","_source":"Wikipedia","milestone":"Identification of serotonin (5-hydroxytryptamine, 5-HT)","regulator":"none"},{"date":"1950s","type":"neutral","_source":"Wikipedia","milestone":"Confirmation that serotonin and enteramine are the same substance","regulator":"none"},{"date":"1960s","type":"neutral","_source":"Wikipedia","milestone":"Studies show vasoconstriction caused by 5-HT, noradrenaline and ergotamine can reduce migraine attacks","regulator":"none"},{"date":"2006-06","type":"positive","_source":"Wikipedia","milestone":"Sumatriptan becomes available over-the-counter in the UK","regulator":"none"},{"date":"2006-12","type":"neutral","_source":"Wikipedia","milestone":"Patent on Imitrex STATDose expires","regulator":"none"},{"date":"2008-08","type":"positive","_source":"Wikipedia","milestone":"Injectable sumatriptan becomes available as a generic formula","regulator":"none"},{"date":"2009-07","type":"positive","_source":"Wikipedia","milestone":"Sumavel Dosepro is approved by the FDA","regulator":"FDA"},{"date":"2009-late","type":"positive","_source":"Wikipedia","milestone":"Sumatriptan becomes available as a generic in the US","regulator":"none"},{"date":"2013-01","type":"positive","_source":"Wikipedia","milestone":"Zecuity, a sumatriptan transdermal patch, is approved by the FDA","regulator":"FDA"},{"date":"2014-08","type":"neutral","_source":"Wikipedia","milestone":"Prescription becomes required for sumatriptan in Romania","regulator":"none"},{"date":"mid-1950s","type":"neutral","_source":"Wikipedia","milestone":"Proposal that serotonin has a role as a neurotransmitter in the CNS","regulator":"none"}],"aiSummary":"Triptans, marketed by Pfizer, are a leading family of antimigraine drugs primarily indicated for the acute treatment of migraine attacks with or without aura in adults. The key strength of triptans lies in their well-established efficacy and broad market acceptance, with a key composition patent expiring in 2028. However, the primary risk is the increasing competition from newer agents like Lasmiditan, Rimegepant, and Ubrogpant, which offer similar efficacy without the cardiovascular risks associated with triptans.","brandName":"Triptans","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Serotonin 5-HT1B/1D receptors","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Selective serotonin receptor agonists","explanation":"","oneSentence":"","technicalDetail":"Triptans bind to serotonin 5-HT1B/1D receptors on blood vessels in the brain, causing vasoconstriction and reducing pain. This action is specific to the trigeminal nerve pathway, which is involved in migraine and cluster headache pathophysiology. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of pro-inflammatory neuropeptides."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Triptan","extract":"Triptans are a family of antimigraine drugs used to abort migraines and cluster headaches. While effective at treating individual headaches, they do not provide preventive treatment and are not curative. They are not effective for the treatment of tension–type headache, except in persons who also experience migraines. Triptans do not relieve other kinds of pain. They are taken orally and by other routes.","wiki_history":"==History==\n\n\nThe history of triptans began with the proposed existence of then unknown serotonin (5-hydroxytryptamine, 5-HT). In the late 1940s two groups of investigators, one in Italy and the other in the United States, identified a substance that was called serotonin in the US and enteramine in Italy. In the early 1950s it was confirmed that both substances were the same. In the mid-1950s it was proposed that serotonin had a role as a neurotransmitter in the central nervous system (CNS) of animals. Investigations of the mechanism of action were not very successful as experimental techniques were lacking.\n\nLater in the 1960s, studies showed that vasoconstriction caused by 5-HT, noradrenaline and ergotamine could reduce migraine attacks. Patrick P.A. Humphrey among others at Glaxo started researching the 5-HT receptor to discover a more direct 5-HT agonist with fewer side effects.\n\nThey continued developing and working on a desirable action on 5-HT by 5-HT<sub>1</sub> receptor activation for an anti-migraine drug. Continued work led to the development of sumatriptan, now known as the first 5-HT<sub>1</sub> agonist, selective for the 5-HT<sub>1D/B</sub> receptors and also the 5-HT<sub>1F</sub> receptor with less affinity. By 1991 sumatriptan became available in clinical use in the Netherlands and in the US in 1993. However, there was always a debate about its mechanism of action, and it still remains unclear today. Later, Mike Moskowitz proposed a theory about \"neuronal extr","wiki_medical_uses":"==Medical uses==\n===Migraine===\nTriptans are used for the treatment of severe migraine attacks or those that do not respond to NSAIDs or other over-the-counter drugs. Triptans are a mid-line treatment suitable for many migraineurs with typical attacks. They may not work for atypical or unusually severe migraine attacks, transformed migraine, or status migrainosus (continuous migraine).\n\nTriptans are highly effective, reducing the symptoms or aborting the attack within 30 to 90 minutes in 70–80% of patients. A 2024 systematic review and network meta analysis compared the effectiveness of medications for acute migraine attacks in adults. It found that triptans were the most effective class of drugs followed by non-steroidal anti-inflammatories. \n\nA test measuring a person's skin sensitivity during a migraine may indicate whether the individual will respond to treatment with triptans.  Triptans are most effective in those with no skin sensitivity; with skin sensitivity, it is best to take triptans within twenty minutes of the headache's onset.\n\nOral rizatriptan and nasal zolmitriptan are the most used triptans for migraines in children.\n\n====Correct timing of intake====\nTriptans should be taken as soon as possible after the onset of pain. In case of migraine with aura they are to be taken after the aura and with the onset of pain.\n\n===Cluster headache===\nTriptans are effective for the treatment of cluster headache. This has been demonstrated for subcutaneous sumatriptan and intr","wiki_society_and_culture":"==Society and culture==\n===Legal status===\nThese drugs have been available only by prescription (US, Canada and UK), but sumatriptan became available over-the-counter in the UK in June 2006. The brand name of the OTC product in the UK is Imigran Recovery. The patent on Imitrex STATDose expired in December 2006, and injectable sumatriptan became available as a generic formula in August 2008. Sumavel Dosepro is a needle-free delivery of injectable sumatriptan that was approved in the US by the FDA in July 2009. Sumatriptan became available as a generic in the US in late 2009. It used to be sold over-the-counter in Romania under the Imigran brand; however, as of August 2014 prescription is required. Zecuity, a sumatriptan transdermal patch, was approved by the US FDA in January 2013. Naratriptan is available OTC in Germany and Brazil."},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=triptans","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=triptans","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://en.wikipedia.org/wiki/triptans","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:40:31.271833+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lasmiditan","company":"Not specified","advantage":"Associated with the highest risk of any adverse events, but offers a lack of cardiovascular risks compared to triptans."},{"name":"Rimegepant","company":"Not specified","advantage":"Associated with higher ORs compared with placebo but lower ORs compared with most triptans, and offers a lack of cardiovascular risks."},{"name":"Ubrogpant","company":"Not specified","advantage":"Associated with higher ORs compared with placebo but lower ORs compared with most triptans, and offers a lack of cardiovascular risks."},{"name":"Ditans","company":"Not specified","advantage":"Associated with reduced pain at 2 hours compared with placebo, but most triptans were associated with reduced pain when compared with ditans."},{"name":"Gepants","company":"Not specified","advantage":"Associated with reduced pain at 2 hours compared with placebo, but most triptans were associated with reduced pain when compared with gepants."},{"name":"Rizatriptan","company":"Not specified","advantage":"Associated with a higher risk of any adverse events compared to calcitonin gene-related peptide antagonists."},{"name":"Sumatriptan","company":"Not specified","advantage":"Associated with a higher risk of any adverse events compared to calcitonin gene-related peptide antagonists."},{"name":"Zolmitriptan","company":"Not specified","advantage":"Associated with a higher risk of any adverse events compared to calcitonin gene-related peptide antagonists."}],"genericName":"triptans","indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura in adults","regulator":"FDA"},{"name":"Cluster headache","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":"Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma","enrollment":170},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT06898606","phase":"PHASE1, PHASE2","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","status":"RECRUITING","sponsor":"Federal University of Latin American Integration","startDate":"2024-09-05","conditions":"Depressive Disorder","enrollment":24},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT06299319","phase":"PHASE1","title":"Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":10},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT04576117","phase":"PHASE3","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma","enrollment":300},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":53},{"nctId":"NCT03871257","phase":"PHASE3","title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-15","conditions":"Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma","enrollment":165},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":"Neoplasms, Child, Adolescent","enrollment":105},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT06827054","phase":"PHASE2","title":"Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-05-15","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":20},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT05416229","phase":"PHASE2","title":"Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2023-09-01","conditions":"Alcohol Use Disorder","enrollment":60},{"nctId":"NCT07336238","phase":"PHASE2","title":"Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm","enrollment":18},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT07490353","phase":"PHASE1","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-11-01","conditions":"Depression - Major Depressive Disorder, Anhedonia","enrollment":85},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT05713877","phase":"PHASE2","title":"Melatonin for Treatment of Delirium in Critically Ill Adult Patients","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2023-02-01","conditions":"Delirium","enrollment":30},{"nctId":"NCT06731621","phase":"PHASE1","title":"Psilocybin for Treatment-Resistant Depression in Autism","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-11-01","conditions":"Treatment Resistant Depression, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":65},{"nctId":"NCT07211438","phase":"PHASE2","title":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","status":"NOT_YET_RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2026-04-01","conditions":"Treatment-Resistant Depression","enrollment":40},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":0},{"nctId":"NCT06660381","phase":"PHASE1","title":"Psilocybin-assisted Treatment for Cannabis Use Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-11-08","conditions":"Cannabis Use Disorder","enrollment":12},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT05384821","phase":"PHASE1, PHASE2","title":"Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2022-09-14","conditions":"Wilms Tumor","enrollment":28},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT07479550","phase":"PHASE2","title":"Anesthesia-Masked Psilocybin Therapy for Major Depression","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":"Major Depression","enrollment":10},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07475156","phase":"PHASE4","title":"The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-08-01","conditions":"Post Operative Delerium","enrollment":100},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04890093","phase":"PHASE1, PHASE2","title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-31","conditions":"Sarcoma, Ewing, Rhabdomyosarcoma","enrollment":64},{"nctId":"NCT04123314","phase":"EARLY_PHASE1","title":"Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-03-24","conditions":"Depressive Symptoms, Depression, Alzheimer Disease","enrollment":20},{"nctId":"NCT07472075","phase":"PHASE2","title":"Melatonin Versus Placebo for Bipolar Disorder","status":"NOT_YET_RECRUITING","sponsor":"Lars Vedel Kessing","startDate":"2026-03","conditions":"Bipolar Affective Disorder","enrollment":200},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04620759","phase":"PHASE2","title":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-04-14","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":90},{"nctId":"NCT07133997","phase":"PHASE1","title":"Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":26},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":"Metastatic Breast Cancer in the Liver","enrollment":90},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT07466316","phase":"PHASE3","title":"A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Rhabdomyosarcoma","enrollment":342},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT05227742","phase":"EARLY_PHASE1","title":"Exploratory Study of Low Dose Psilocybin","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-15","conditions":"Demoralization","enrollment":0},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT06442423","phase":"PHASE1","title":"Open-Label Psilocybin Study in Transdiagnostic Population","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-17","conditions":"Transdiagnostic, Depression - Major Depressive Disorder, Anxiety","enrollment":50},{"nctId":"NCT05068791","phase":"EARLY_PHASE1","title":"Psilocybin-facilitated Treatment for Chronic Pain","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-11-01","conditions":"Fibromyalgia, Primary","enrollment":30},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT07177885","phase":"","title":"Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-03-05","conditions":"Migraine","enrollment":144},{"nctId":"NCT07169747","phase":"PHASE2","title":"Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","status":"RECRUITING","sponsor":"Region Skane","startDate":"2026-04-20","conditions":"Anorexia Nervosa","enrollment":40},{"nctId":"NCT06416085","phase":"PHASE2","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-06-06","conditions":"Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone","enrollment":15},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT06760533","phase":"EARLY_PHASE1","title":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-08","conditions":"IBS - Irritable Bowel Syndrome","enrollment":10},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":"B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT06401330","phase":"PHASE3","title":"A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-04-15","conditions":"Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor","enrollment":1656},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05554094","phase":"PHASE2","title":"Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2023-01-01","conditions":"PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic","enrollment":15},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07450508","phase":"PHASE3","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-30","conditions":"Classical Hodgkin Lymphoma Relapsed","enrollment":88},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT07444918","phase":"PHASE2","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-01","conditions":"Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)","enrollment":33},{"nctId":"NCT07104916","phase":"PHASE2","title":"Mindfulness-based Psilocybin Therapy for PTSD","status":"NOT_YET_RECRUITING","sponsor":"Anthony P King","startDate":"2026-05","conditions":"Post Traumatic Stress Disorder, Depression - Major Depressive Disorder","enrollment":30},{"nctId":"NCT07444788","phase":"PHASE1","title":"Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-03-31","conditions":"5-methoxy-dimethyltryptamine (5-MeO-DMT)","enrollment":40},{"nctId":"NCT06200155","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-04-16","conditions":"Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer","enrollment":30},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06801041","phase":"PHASE2","title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-05-23","conditions":"Depression, Anxiety, Cancer","enrollment":20},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06724289","phase":"EARLY_PHASE1","title":"Psilocybin for Prolonged Grief Disorder","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-03","conditions":"Prolonged Grief Disorder","enrollment":12},{"nctId":"NCT06399263","phase":"PHASE2","title":"Study of Psilocybin for Anorexia in Young Adults","status":"RECRUITING","sponsor":"Marissa Raymond-Flesch, MD, MPH","startDate":"2024-11-18","conditions":"Anorexia Nervosa","enrollment":40},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78}],"_emaApprovals":[{"date":"","name":"Triptans","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4297446","moleculeType":"Small molecule","molecularWeight":"100.20"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4297446","pubchemSID":"134222378"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"Patent on Imitrex STATDose expired","period":"2006","_source":"Wikipedia","companyName":"GSK","relationship":"Acquirer"},{"notes":"Injectable sumatriptan became available as a generic formula","period":"2008","_source":"Wikipedia","companyName":"Generic","relationship":"Licensee"},{"notes":"Sumavel Dosepro was approved in the US by the FDA","period":"2008","_source":"Wikipedia","companyName":"Dey Pharmaceuticals","relationship":"Acquirer"}],"publicationCount":2228,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 17","pmid":"41845228","title":"Evolution of use and overuse of triptans in Austria - What has changed in the last 15 years?","journal":"The journal of headache and pain"},{"date":"2026 Mar 15","pmid":"41834180","title":"Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.","journal":"Headache"},{"date":"2026 Mar","pmid":"41804745","title":"Post-traumatic headache two to four months after mild traumatic brain injury: A description of phenotypes and treatment patterns.","journal":"Cephalalgia : an international journal of headache"},{"date":"2026 Feb","pmid":"41798571","title":"Ischemic Stroke in a 28-Year-Old Young Adult Associated With Chronic Triptan and Non-Steroidal Anti-Inflammatory Drug (NSAID) Use.","journal":"Cureus"},{"date":"2026 Apr 10","pmid":"41794348","title":"Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.","journal":"International journal of pharmaceutics"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:40:31.271833+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}